Jay Lee, MD, talks about financial toxicity in terms of the individual patient and in terms of the health system itself, especially in terms of non-small cell lung cancer (NSCLC) recurrence.
Jay Lee, MD, thoracic surgeon, surgical director, thoracic oncology program, University of California Los Angeles Health, division of thoracic surgery, and presenter at the CHEST Annual Meeting 2023 discusses the cost of financial toxicity in patients with non-small cell lung cancer (NSCLC) who experienced a recurrence and those who didn’t.
Transcript
What role does financial toxicity play in in the treatment of NSCLC?
Financial toxicity can be looked at in 2 ways. One is at the personal patient level and what kind of financial responsibilities are they faced with? And then also, financial toxicity in the reimbursement at the insurance claims level where health care resource utilization can be seen system wide. It's hard to collect data on the patient portion and what their financial responsibilities are.
However, we did look at the Sears Medicare database and looked at claims and associated costs of patients in the early stage [NSCLC] setting that have surgery. When patients develop recurrences versus no recurrences, inherently, we expect that cost will be higher when a patient develops a recurrence, but there hasn't been a whole lot of data about what those numbers actually are.
We reported on real world data analysis from the Medicare Sears database, and what we found was that when you look at health care resources, including inpatient visits, outpatient visits, physician services and emergency department visits, all of those resources were higher in patients that had recurrences. When we define a health care unit as per patient per month health care resource utilization—we defined this as PPPM in our in our reports that we have published on—what we find is that the average per patient per month cost when a patient develops a recurrence is roughly about $7,400. Compared to a patient that doesn't develop recurrence, it's about $1,100 per patient per month.
So, there's a significant difference in in the financial toxicity to the health system overall, in patients that develop a recurrence. This really points to the importance of preventing recurrences, not only because it's important as a surrogate for overall survival, but it's also beneficial from a financial perspective to reduce recurrences to the health care system.
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Budesonide-Based Triple Therapy Shows Best Benefit Over Dual Therapy for COPD
May 8th 2024The triple therapy of budesonide, glycopyrrolate, and formoterol fumarate showed the greatest incremental net benefit among a series of triple therapy medications that were evaluated against dual therapy for chronic obstructive pulmonary disease (COPD), according to an analysis presented at ISPOR.
Read More